CA3166579A1 - Improved methods and compositions for cromakalim prodrug therapy - Google Patents

Improved methods and compositions for cromakalim prodrug therapy Download PDF

Info

Publication number
CA3166579A1
CA3166579A1 CA3166579A CA3166579A CA3166579A1 CA 3166579 A1 CA3166579 A1 CA 3166579A1 CA 3166579 A CA3166579 A CA 3166579A CA 3166579 A CA3166579 A CA 3166579A CA 3166579 A1 CA3166579 A1 CA 3166579A1
Authority
CA
Canada
Prior art keywords
formula
pharmaceutically acceptable
cklp1
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3166579A
Other languages
English (en)
French (fr)
Inventor
Thurein M. Htoo
Barbara M. WIROSTKO
Michael P. Fautsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qlaris Bio Inc
Mayo Foundation for Medical Education and Research
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3166579A1 publication Critical patent/CA3166579A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA3166579A 2020-02-07 2021-02-05 Improved methods and compositions for cromakalim prodrug therapy Pending CA3166579A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062971752P 2020-02-07 2020-02-07
US62/971,752 2020-02-07
US202063120604P 2020-12-02 2020-12-02
US63/120,604 2020-12-02
US202163134042P 2021-01-05 2021-01-05
US63/134,042 2021-01-05
PCT/US2021/016920 WO2021158992A1 (en) 2020-02-07 2021-02-05 Improved methods and compositions for cromakalim prodrug therapy

Publications (1)

Publication Number Publication Date
CA3166579A1 true CA3166579A1 (en) 2021-08-12

Family

ID=77199473

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3166579A Pending CA3166579A1 (en) 2020-02-07 2021-02-05 Improved methods and compositions for cromakalim prodrug therapy

Country Status (7)

Country Link
US (1) US20220387457A1 (https=)
EP (1) EP4100003A4 (https=)
JP (1) JP2023512828A (https=)
CN (1) CN115768419A (https=)
AU (1) AU2021215932A1 (https=)
CA (1) CA3166579A1 (https=)
WO (1) WO2021158992A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10981951B2 (en) * 2014-01-31 2021-04-20 Mayo Foundation For Medical Education And Research Therapeutics for the treatment of glaucoma
CA3159771A1 (en) 2019-12-12 2021-06-17 Thurein M. Htoo Controlled-delivery cromakalim prodrugs
EP4384162A4 (en) * 2021-08-12 2025-06-04 Qlaris Bio, Inc. Compositions and methods for extended-release bromo-kallim therapy
CN115058440B (zh) * 2022-06-08 2023-08-15 郑州轻工业大学 催化合成天然蔗糖酯的工程菌及其构建方法和应用
GB202211936D0 (en) * 2022-08-16 2022-09-28 Royal Veterinary College Method and treatment for diabetes
IL320428A (en) * 2022-11-04 2025-06-01 Qlaris Bio Inc Topical ophthalmic administration of cromolyns
CN119548509B (zh) * 2024-11-21 2025-11-14 中山大学中山眼科中心 一种小分子化合物组合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308062D0 (en) * 1983-03-24 1983-05-05 Beecham Group Plc Active compounds
WO1989010757A1 (en) * 1988-05-10 1989-11-16 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis New ophthalmic preparation for treating glaucoma
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
CN101327325A (zh) * 2002-07-30 2008-12-24 奥默罗斯公司 眼科冲洗液及方法
DK2838533T3 (da) * 2012-04-16 2017-11-27 Univ Case Western Reserve Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet
US10981951B2 (en) * 2014-01-31 2021-04-20 Mayo Foundation For Medical Education And Research Therapeutics for the treatment of glaucoma
MA41252A (fr) * 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
WO2018047175A1 (en) * 2016-09-08 2018-03-15 Regenera Pharma Ltd. Compositions comprising triterpenoids and uses thereof for treating optic neuropathy
CA3159771A1 (en) * 2019-12-12 2021-06-17 Thurein M. Htoo Controlled-delivery cromakalim prodrugs

Also Published As

Publication number Publication date
WO2021158992A1 (en) 2021-08-12
US20220387457A1 (en) 2022-12-08
AU2021215932A1 (en) 2022-09-15
JP2023512828A (ja) 2023-03-29
EP4100003A1 (en) 2022-12-14
EP4100003A4 (en) 2024-04-24
CN115768419A (zh) 2023-03-07

Similar Documents

Publication Publication Date Title
US20220387457A1 (en) Methods and compositions for cromakalim prodrug therapy
EP1802373B1 (en) Carboxy-amido-triazoles for the localized teatment of ocular diseases
US12454539B2 (en) Controlled-delivery cromakalim prodrugs
US6806268B2 (en) Method for treating glaucoma V
US20240285580A1 (en) Compositions and methods for extended release cromakalim therapy
EA024042B1 (ru) Способ снижения внутриглазного давления у людей
CA2546053A1 (en) Amelioration of cataracts, macular degeneration and other ophthalmic diseases
US20050131025A1 (en) Amelioration of cataracts, macular degeneration and other ophthalmic diseases
JP2013523739A (ja) Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
US9629826B2 (en) CAI-based systems and methods for the localized treatment of uveitis
EP3733179A1 (en) Pharmaceutical preparation containing pyridyl aminoacetic acid compound
US20190275022A1 (en) Methods, compositions, and compounds for treatment of dermatological and ocular conditions
WO2016061378A1 (en) Cai-based systems and methods for the localized treatment of uveitis
ZA200604402B (en) Amelioration of cataracts, macular degeneration and other ophthalmic diseases
AU2002312128A1 (en) Method for treating glaucoma V

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241216

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241216

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241216

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260319